Dechra Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dechra Pharmaceuticals
Type Public (LSEDPH)
Industry Pharmaceuticals
Founded 1997
Headquarters Stoke-on-Trent, England
Key people Michael Redmond, (Chairman)
Ian Page, (CEO)
Products Felimazola, Vetoryl
Revenue £189.2 million (2013)[1]
Operating income £39.1 million (2013)[1]
Net income £17.9 million (2013)[1]
Website www.dechra.com

Dechra Pharmaceuticals plc is an English-based manufacturer of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

History[edit]

The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62m.[3] It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[4]

Operations[edit]

The Company sells pharmaceuticals - mainly for dogs, cats and horses; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.[5]

See also[edit]

References[edit]